Dr. Matthew Davids on advances in CLL treatment | Dana-Farber Cancer Institute

Matthew Davids, MD, MMSc shares updates from the ASH 2017 Annual Meeting on advances in treating newly-diagnosed and relapsed CLL. New approaches include ibrutinib + FCR for younger, newly-diagnosed patients and a combination of rituximab and venetoclax for relapsed patients. Learn more about Dana-Farber’s Center for Chronic Lymphocytic Leukemia. http://www.dana-farber.org/center-for-chronic-lymphocytic-leukemia/

Category: News
About The Author

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>